Intellia Therapeutics, Inc. (0JBU.L)
USD 12.59
(-6.07%)
USD 12.59
(-6.07%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 36.27 Million USD | -30.4% |
| 2022 | 52.12 Million USD | 57.69% |
| 2021 | 33.05 Million USD | -43.01% |
| 2020 | 57.99 Million USD | 34.55% |
| 2019 | 43.1 Million USD | 41.63% |
| 2018 | 30.43 Million USD | 16.53% |
| 2017 | 26.11 Million USD | 58.49% |
| 2016 | 16.47 Million USD | 172.65% |
| 2015 | 6.04 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 28.93 Million USD | 1609.39% |
| 2024 Q2 | 6.95 Million USD | -75.96% |
| 2023 Q2 | 13.59 Million USD | 7.84% |
| 2023 FY | 36.27 Million USD | -30.4% |
| 2023 Q4 | -1.91 Million USD | -115.99% |
| 2023 Q1 | 12.6 Million USD | -7.12% |
| 2023 Q3 | 11.99 Million USD | -11.78% |
| 2022 Q1 | 11.25 Million USD | -12.46% |
| 2022 Q4 | 13.57 Million USD | 2.31% |
| 2022 Q3 | 13.26 Million USD | -5.45% |
| 2022 Q2 | 14.03 Million USD | 24.69% |
| 2022 FY | 52.12 Million USD | 57.69% |
| 2021 Q3 | 7.2 Million USD | 9.98% |
| 2021 Q4 | 12.85 Million USD | 78.43% |
| 2021 FY | 33.05 Million USD | -43.01% |
| 2021 Q1 | 6.44 Million USD | -2.27% |
| 2021 Q2 | 6.55 Million USD | 1.63% |
| 2020 Q4 | 6.59 Million USD | -70.32% |
| 2020 FY | 57.99 Million USD | 34.55% |
| 2020 Q1 | 12.91 Million USD | 18.11% |
| 2020 Q3 | 22.22 Million USD | 36.63% |
| 2020 Q2 | 16.26 Million USD | 25.91% |
| 2019 Q3 | 10.61 Million USD | -4.52% |
| 2019 FY | 43.1 Million USD | 41.63% |
| 2019 Q1 | 10.43 Million USD | 32.4% |
| 2019 Q4 | 10.93 Million USD | 3.01% |
| 2019 Q2 | 11.11 Million USD | 6.57% |
| 2018 Q4 | 7.88 Million USD | 6.37% |
| 2018 FY | 30.43 Million USD | 16.53% |
| 2018 Q3 | 7.4 Million USD | -3.5% |
| 2018 Q2 | 7.67 Million USD | 2.78% |
| 2018 Q1 | 7.46 Million USD | 12.01% |
| 2017 FY | 26.11 Million USD | 58.49% |
| 2017 Q3 | 7.31 Million USD | 23.66% |
| 2017 Q2 | 5.91 Million USD | -4.79% |
| 2017 Q4 | 6.66 Million USD | -8.87% |
| 2017 Q1 | 6.21 Million USD | 10.45% |
| 2016 FY | 16.47 Million USD | 172.65% |
| 2016 Q4 | 5.62 Million USD | 15.57% |
| 2016 Q3 | 4.86 Million USD | 15.76% |
| 2016 Q2 | 4.2 Million USD | 136.69% |
| 2016 Q1 | 1.77 Million USD | 4.96% |
| 2015 FY | 6.04 Million USD | 0.0% |
| 2015 Q3 | 1.68 Million USD | 22.59% |
| 2015 Q4 | 1.69 Million USD | 0.3% |
| 2015 Q1 | 1.28 Million USD | 0.0% |
| 2015 Q2 | 1.37 Million USD | 7.08% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | 53.567% |
| Dynavax Technologies Corporation | 232.28 Million USD | 84.383% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 94.029% |
| Perrigo Company plc | 4.65 Billion USD | 99.221% |
| Illumina, Inc. | 4.5 Billion USD | 99.195% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.915% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -2950.883% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.975% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 99.758% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 71.447% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.723% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | 98.773% |
| Biogen Inc. | 9.83 Billion USD | 99.631% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 79.416% |
| Evolus, Inc. | 202.08 Million USD | 82.05% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -73.002% |
| bluebird bio, Inc. | 29.49 Million USD | -22.979% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 68.818% |
| FibroGen, Inc. | 147.75 Million USD | 75.449% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 99.469% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 645.407% |
| Geron Corporation | 237 Thousand USD | -15205.907% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 98.016% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 90.917% |
| Myriad Genetics, Inc. | 678.4 Million USD | 94.653% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 8.54 Billion USD | 99.575% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -936.429% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 99.042% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 98.501% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.632% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 95.395% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -323.131% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | 59.749% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 86.595% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -16.084% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 97.082% |
| OPKO Health, Inc. | 863.49 Million USD | 95.799% |
| Exelixis, Inc. | 1.83 Billion USD | 98.018% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 98.078% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 92.48% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -128.965% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | 85.454% |
| Insmed Incorporated | 305.2 Million USD | 88.115% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 95.626% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -35.238% |
| TG Therapeutics, Inc. | 233.66 Million USD | 84.475% |
| Incyte Corporation | 3.69 Billion USD | 99.018% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 96.543% |